Regeneron Pharmaceuticals, Inc. (REGN) Shareholders & Insider Trades
Regeneron Pharmaceuticals shareholders at a glance
The largest holder of Regeneron Pharmaceuticals stock is Vanguard Capital Management LLC, with 6.6 million shares (6.55% of the company), worth about $5.30 billion as of September 25, 2026. The 10 largest holders together own 41.0%.
In Q2 2026, 1,413 institutional holdings reports listed shares worth $58.40 billion.
Insiders reported 61 transactions in the last two years: 11 sales worth $10.32 million and no purchases. The newest one on file is from May 1, 2026 (Ryan Arthur F, Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 1, 2026.
Regeneron Pharmaceuticals, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Regeneron Pharmaceuticals shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Vanguard Capital Management LLC | 6.6 million | 6.55% | $5.3B |
| BlackRock Advisors LLC | 6.5 million | 6.46% | $5.2B |
| Dodge & Cox | 4.9 million | 4.82% | $3.9B |
| State Street Corporation | 4.8 million | 4.78% | $3.9B |
| Invesco Advisers, Inc. | 3.9 million | 3.90% | $3.1B |
| JPMorgan Investment Management, Inc. | 3.8 million | 3.73% | $3.0B |
| Vanguard Portfolio Management LLC | 3.2 million | 3.14% | $2.5B |
| Fiduciary Trust Company International | 2.7 million | 2.68% | $2.2B |
| Geode Capital Management LLC | 2.6 million | 2.60% | $2.1B |
| BlackRock Life Ltd. | 2.3 million | 2.30% | $1.9B |
As of September 25, 2026.
Regeneron Pharmaceuticals institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 1,413 | – | $58.4B |
| Q1 2026 | 1,475 | 90.5 million | $69.8B |
| Q4 2025 | 1,473 | 91.9 million | $70.9B |
| Q3 2025 | 1,328 | 91.2 million | $51.3B |
| Q2 2025 | 1,293 | 90.6 million | $47.6B |
| Q1 2025 | 1,372 | 93.5 million | $59.2B |
| Q4 2024 | 1,419 | 93.7 million | $66.8B |
| Q3 2024 | 1,485 | 102.0 million | $106.0B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Regeneron Pharmaceuticals insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Ryan Arthur F | May 1, 2026 | Director | Sale at price 701.76 - 714.13 per share. | $70,524 |
| Ryan Arthur F | Apr 1, 2026 | Director | Sale at price 771.32 - 779.71 per share. | $77,727 |
| Ryan Arthur F | Mar 2, 2026 | Director | Sale at price 777.46 - 789.28 per share. | $78,550 |
| Zoghbi Huda Y | Feb 19, 2026 | Director | Conversion of Exercise of derivative security at price 376.69 per share. | $617,018 |
| Zoghbi Huda Y | Feb 19, 2026 | Director | Sale at price 774.68 - 790.00 per share. | $1.3M |
| Pitofsky Jason | Feb 9, 2026 | Officer | Conversion of Exercise of derivative security at price 492.00 per share. | $492,000 |
| Pitofsky Jason | Feb 9, 2026 | Officer | Sale at price 775.95 - 785.72 per share. | $1.6M |
| Ryan Arthur F | Feb 9, 2026 | Director | Sale at price 775.63 - 787.82 per share. | $77,853 |
| Bassler Bonnie L | Jan 7, 2026 | Director | Conversion of Exercise of derivative security at price 374.12 per share. | $561,180 |
| Bassler Bonnie L | Jan 7, 2026 | Director | Sale at price 800.00 per share. | $1.2M |
| Thompson Craig B | Jan 2, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Schenkein David P | Jan 2, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
Newest 12 of 61 insider transactions in the last two years.
Questions and answers
Who owns the most Regeneron Pharmaceuticals stock?
Vanguard Capital Management LLC, with 6.55% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (6.46%) and Dodge & Cox (4.82%).
How many institutions own Regeneron Pharmaceuticals stock?
1,413 institutional holdings reports listed Regeneron Pharmaceuticals shares in Q2 2026 worth $58.40 billion.
Are Regeneron Pharmaceuticals insiders buying or selling the stock?
In the last two years insiders reported 11 sales and no purchases (61 transactions in all); the newest on file is from May 1, 2026.
